Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. INFY
4. RNG
5. AMD
6. URI
7. EW
8. GRC
9. INFO:IN
10. COLB

Go back to Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
(NASDAQ: KLRS) Delayed: 3.92 --0 (-0%)
Previous Close $3.92    52 Week High $ 
Open $3.92    52 Week Low $ 
Day High $3.92    P/E N/A 
Day Low $3.92    EPS $ 
Volume 122